newsfilter
← Latest News
Business Wire·

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose